| Autor: |
Søren Søgaard Lund, Yan Gong |
| Předmět: |
|
| Zdroj: |
Diabetes Care; Jan2014, Vol. 37 Issue 1, pe19-e20, 2p |
| Abstrakt: |
The authors discuss the effects of metformin versus glipizide in type 2 diabetic (T2D) patients with coronary artery disease. They cite the randomized clinical trial (RCT) carried out by J. Hong and colleagues, which showed that three years of metformin treatment was linked with substantially lower cardiovascular (CV) risk. They cite the UK Prospective Diabetes Study (UKPDS), which is the landmark study establishing metformin's cardioprotective reputation. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
